Last updated: February 19, 2026
This report analyzes Canadian patent CA3113166, which claims the compound ritlecitinib, pharmaceutical compositions containing it, and methods of treating conditions associated with Janus Kinase (JAK) inhibition. The patent is owned by Pfizer Inc. and has a grant date of October 28, 2021.
What is the Core Invention Claimed in CA3113166?
The primary claims of CA3113166 revolve around the novel compound 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile, also known as ritlecitinib. The patent also covers pharmaceutical compositions incorporating this compound and methods for treating immune-mediated inflammatory diseases and certain cancers by inhibiting JAK family kinases.
The patent details the synthesis and characterization of ritlecitinib, identifying it as a potent inhibitor of JAK kinases, particularly JAK3 and TEC kinase. This dual inhibition is presented as a key differentiator, offering a distinct therapeutic profile.
Key Compound Structure:
- Chemical Name: 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile
- Common Name: Ritlecitinib
Claimed Therapeutic Targets:
- Inhibition of JAK family kinases (JAK1, JAK2, JAK3, TYK2)
- Inhibition of TEC kinase
The patent emphasizes the selective inhibition profile of ritlecitinib, suggesting it offers an improved therapeutic index compared to less selective JAK inhibitors.
What Specific Diseases and Conditions are Targeted?
CA3113166 claims methods of treating a broad range of immune-mediated inflammatory diseases and certain cancers. The rationale for targeting these conditions is based on the role of JAK signaling pathways in mediating inflammation and immune responses.
Claimed Indications:
- Immune-Mediated Inflammatory Diseases:
- Rheumatoid arthritis
- Psoriasis
- Psoriatic arthritis
- Inflammatory bowel disease (including Crohn's disease and ulcerative colitis)
- Alopecia areata
- Atopic dermatitis
- Systemic lupus erythematosus
- Myasthenia gravis
- Type 1 diabetes
- Graft-versus-host disease
- Ankylosing spondylitis
- Uveitis
- Cancers:
- Hematologic malignancies (e.g., lymphomas, leukemias)
- Solid tumors where JAK signaling is implicated
The patent describes methods of administering ritlecitinib in dosages effective to reduce inflammation, modulate immune responses, and inhibit disease progression in these specified conditions. The specific dosages and administration frequencies are not explicitly detailed within the core compound and method claims but are foundational to the practical application of the invention.
What are the Key Technical Aspects of the Patent?
The patent provides detailed information regarding the chemical synthesis, polymorphic forms, and specific therapeutic utility of ritlecitinib. It also includes data supporting its efficacy and selectivity.
Synthesis and Characterization:
- The patent outlines synthetic routes to ritlecitinib, including specific reagents, reaction conditions, and purification methods. Examples of synthetic steps are provided.
- Detailed characterization data, including spectroscopic information (NMR, Mass Spectrometry) and physicochemical properties, are presented to define the compound.
Polymorphic Forms:
- The patent claims specific crystalline forms (polymorphs) of ritlecitinib. These polymorphic forms are crucial for formulation development, as they can affect stability, dissolution rates, and bioavailability.
- Examples of identified polymorphs are provided, along with their characterization using techniques such as X-ray powder diffraction (XRPD) and differential scanning calorimetry (DSC).
Biological Activity and Selectivity:
- In vitro assays demonstrating the inhibitory activity of ritlecitinib against JAK family kinases (JAK1, JAK2, JAK3, TYK2) and TEC kinase are detailed.
- Selectivity data is presented, comparing ritlecitinib's potency against target kinases versus off-target kinases. This data supports the claimed advantages of a potentially improved safety profile and reduced side effects.
- In vivo studies in animal models of inflammatory diseases are described, showing reduction in disease markers and inflammatory cytokines upon administration of ritlecitinib.
Pharmaceutical Compositions:
- The patent claims pharmaceutical compositions comprising ritlecitinib and one or more pharmaceutically acceptable carriers, diluents, or excipients.
- These compositions are formulated for various routes of administration, including oral, parenteral, and topical.
What is the Patent Status and Term in Canada?
Canadian patent CA3113166 was granted on October 28, 2021. The patent term in Canada is generally 20 years from the filing date, subject to the payment of maintenance fees.
Patent Details:
- Patent Number: CA3113166
- Grant Date: October 28, 2021
- Filing Date: July 10, 2020
- Applicant/Owner: Pfizer Inc.
- Patent Term Expiry (estimated): July 10, 2040 (20 years from filing date, assuming maintenance fees are paid)
The patent is currently in force. Maintenance fees are required to keep the patent in effect. The current status of these fees can be verified through the Canadian Intellectual Property Office (CIPO) database.
What is the Claimed Mechanism of Action for Ritlecitinib?
Ritlecitinib functions by inhibiting Janus Kinase (JAK) enzymes and TEC kinase. JAKs are intracellular enzymes that transmit signals from cytokine and growth factor receptors on the cell surface to the nucleus, thereby influencing gene expression. This signaling cascade is critical for the development and function of immune cells and plays a significant role in inflammatory and autoimmune processes.
Mechanism:
- JAK Inhibition: Ritlecitinib binds to and inhibits JAK family kinases. This blockage prevents the phosphorylation and activation of Signal Transducers and Activators of Transcription (STATs). STATs are transcription factors that, upon activation, move to the nucleus and regulate the expression of genes involved in immune cell differentiation, proliferation, and cytokine production. By inhibiting JAKs, ritlecitinib disrupts the signaling pathways of various pro-inflammatory cytokines, such as IL-2, IL-4, IL-6, IL-7, IL-9, IL-15, and IL-21.
- TEC Kinase Inhibition: Ritlecitinib also inhibits TEC kinase, a non-receptor tyrosine kinase that plays a role in signaling pathways within lymphocytes and myeloid cells. TEC kinase is involved in B-cell receptor (BCR) and T-cell receptor (TCR) signaling, and its inhibition can modulate immune cell activation and function.
- Therapeutic Outcome: The combined inhibition of JAK and TEC kinases leads to a broader suppression of immune cell activation and inflammatory mediator production. This effect is hypothesized to reduce the inflammatory processes underlying autoimmune diseases and to control certain types of cancer where these pathways are dysregulated.
The patent emphasizes the potent and selective inhibition of JAK3 and TEC kinase by ritlecitinib. JAK3 is particularly important for the signaling of common gamma chain cytokines, which are critical for lymphocyte development and function.
What is the Competitive Landscape for JAK Inhibitors in Canada?
The market for JAK inhibitors in Canada is competitive, with several approved drugs and an active pipeline of molecules under development. CA3113166, covering ritlecitinib, enters this landscape as a specific entity with a distinct profile.
Key Approved JAK Inhibitors in Canada (as of recent data, subject to change):
- Tofacitinib (Xeljanz, Xeljanz XR): Approved for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Inhibits JAK1, JAK2, and JAK3.
- Baricitinib (Olumiant): Approved for rheumatoid arthritis and severe alopecia areata. Primarily inhibits JAK1 and JAK2.
- Upadacitinib (Rinvoq): Approved for rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, and Crohn's disease. Primarily inhibits JAK1.
- Filgotinib (Jyseleca): Approved for rheumatoid arthritis and ulcerative colitis. Primarily inhibits JAK1.
- Abrocitinib (Cibinqo): Approved for atopic dermatitis. Primarily inhibits JAK1.
Ritlecitinib's Position:
Ritlecitinib, as claimed in CA3113166, differentiates itself through its claimed potent inhibition of JAK3 and TEC kinase, alongside JAK1. This distinct inhibition profile may offer therapeutic advantages in specific patient populations or for indications where JAK3 and TEC signaling are particularly implicated. The patent indicates ritlecitinib has been developed for conditions like alopecia areata, atopic dermatitis, and vitiligo, areas where other JAK inhibitors have also gained traction.
The competitive landscape includes ongoing research into next-generation JAK inhibitors with improved selectivity and safety profiles. Patent protection, such as that provided by CA3113166, is critical for recouping R&D investments and establishing market exclusivity.
What are the Potential R&D and Investment Implications?
The existence of patent CA3113166 has significant implications for R&D strategy and investment decisions within the pharmaceutical and biotechnology sectors, particularly concerning JAK inhibitors and treatments for inflammatory diseases.
R&D Implications:
- Freedom to Operate: Companies seeking to develop or market JAK inhibitors for indications covered by this patent must conduct thorough freedom-to-operate analyses. Development of compounds with similar mechanisms or for the claimed indications may infringe upon the claims of CA3113166.
- Differentiation Strategy: Research efforts may focus on developing compounds with distinct chemical structures, alternative mechanisms of action, or improved efficacy and safety profiles that do not infringe on existing patents. This could involve targeting different kinases, exploring novel therapeutic pathways, or developing combination therapies.
- Indication Expansion: For companies holding rights to ritlecitinib, the patent provides a foundation for seeking approval in the claimed indications. Future R&D may focus on clinical trials to support expanded indications or to demonstrate superiority over existing treatments in specific patient subgroups.
Investment Implications:
- Market Exclusivity: The patent grants Pfizer Inc. a period of market exclusivity for ritlecitinib and its methods of use in Canada, influencing pricing strategies and market penetration.
- Valuation of Assets: The presence of strong patent protection, such as CA3113166, enhances the valuation of the underlying asset (ritlecitinib) for its owner and for potential licensing or acquisition partners.
- Risk Assessment: Investors evaluating companies in the JAK inhibitor space must assess the strength and scope of patent portfolios, including potential challenges to patent validity or expiration dates, to understand future competitive risks and market opportunities.
- Biosimilar/Generic Development: The patent term expiry date (estimated July 10, 2040) is a critical factor for companies considering the development of generic versions of ritlecitinib, though regulatory hurdles and the potential for new formulations or indications can extend effective market protection.
Key Takeaways
- Canadian patent CA3113166 protects the compound ritlecitinib, pharmaceutical compositions containing it, and methods of treating various immune-mediated inflammatory diseases and certain cancers.
- The patent grants Pfizer Inc. market exclusivity for ritlecitinib in Canada until at least July 10, 2040.
- Ritlecitinib functions as a potent inhibitor of JAK3 and TEC kinase, offering a distinct mechanism compared to some other approved JAK inhibitors.
- The competitive landscape for JAK inhibitors in Canada is robust, with multiple approved drugs. Ritlecitinib's specific inhibition profile is its key differentiator.
- R&D and investment decisions must account for the scope of claims in CA3113166, particularly regarding freedom to operate and strategies for market differentiation.
FAQs
- What is the filing date of Canadian patent CA3113166?
The filing date for Canadian patent CA3113166 is July 10, 2020.
- What are the primary kinases inhibited by ritlecitinib as described in the patent?
The patent describes ritlecitinib as a potent inhibitor of JAK3 and TEC kinase, alongside other JAK family kinases.
- Does Canadian patent CA3113166 cover specific polymorphic forms of ritlecitinib?
Yes, the patent claims specific crystalline forms (polymorphs) of ritlecitinib.
- What is the estimated patent expiry date for CA3113166 in Canada?
Based on a 20-year term from the filing date, the estimated patent expiry date in Canada is July 10, 2040, assuming all maintenance fees are paid.
- Can other companies develop JAK inhibitors for autoimmune diseases in Canada while CA3113166 is in force?
Other companies can develop JAK inhibitors, but they must conduct freedom-to-operate analyses to ensure their compounds and methods of use do not infringe on the specific claims of CA3113166, particularly concerning ritlecitinib and its claimed indications.
Citations
[1] Pfizer Inc. (2021). Canadian Patent CA3113166. Canadian Intellectual Property Office. (Original filing date: July 10, 2020; Grant date: October 28, 2021).
